Xanomeline and trospium chloride

Overview

Cobenfy (xanomeline and trospium chloride) is a first-in-class dual-acting oral medication for the treatment of adults with schizophrenia. It is a combination of an oral M1/M4-preferring muscarinic acetylcholine receptor agonist (xanomeline), which activates M1/M4 receptors in the central nervous system, and a peripheral acting muscarinic acetylcholine receptor antagonist (trospium chloride) that blocks the side effects associated with muscarinic agonism in peripheral tissues.

Cobenfy is designed to work differently from current antipsychotic medicines, which primarily target dopamine or serotonin (5-hydroxytryptamine, 5-HT). It offers a new approach to schizophrenia treatment, with robust efficacy on both positive and negative symptoms associated with the disease.

Currently, Cobenfy is approved in the United States and Mainland China. Zai Lab has an exclusive license from Karuna Therapeutics, Inc., a company acquired by Bristol Myers Squibb, to develop, manufacture, and commercialize Cobenfy in Greater China (mainland China, Hong Kong, Macau, and Taiwan, collectively).